Kun-Wei Song1,2, Tracy Batchelor3. 1. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ksong4@partners.org. 2. Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, MA, 02115, USA. ksong4@partners.org. 3. Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, MA, 02115, USA.
Abstract
PURPOSE OF REVIEW: The optimal treatment for newly diagnosed and refractory or relapsed primary central nervous system lymphoma (PCNSL) is not fully defined. We review the epidemiology, clinical presentation, and current management strategies for newly diagnosed PCNSL as well as emerging treatments for refractory and relapsed disease. RECENT FINDINGS: In recent decades, the incidence of PCNSL has increased in the elderly population. With advancements in chemotherapy for PCNSL, survival has improved. However, outcomes remain inferior when compared with other forms of extranodal lymphoma. Additionally, treatments can be associated with clinically significant neurotoxicities. Despite advances in the treatment of PCNSL, current treatment regimens remain suboptimal in terms of response rates and neurotoxicity. Well-tolerated agents, especially for the elderly, are still needed.
PURPOSE OF REVIEW: The optimal treatment for newly diagnosed and refractory or relapsed primary central nervous system lymphoma (PCNSL) is not fully defined. We review the epidemiology, clinical presentation, and current management strategies for newly diagnosed PCNSL as well as emerging treatments for refractory and relapsed disease. RECENT FINDINGS: In recent decades, the incidence of PCNSL has increased in the elderly population. With advancements in chemotherapy for PCNSL, survival has improved. However, outcomes remain inferior when compared with other forms of extranodal lymphoma. Additionally, treatments can be associated with clinically significant neurotoxicities. Despite advances in the treatment of PCNSL, current treatment regimens remain suboptimal in terms of response rates and neurotoxicity. Well-tolerated agents, especially for the elderly, are still needed.
Authors: Christian Grommes; James L Rubenstein; Lisa M DeAngelis; Andres J M Ferreri; Tracy T Batchelor Journal: Neuro Oncol Date: 2019-02-19 Impact factor: 12.300
Authors: Joe S Mendez; Quinn T Ostrom; Haley Gittleman; Carol Kruchko; Lisa M DeAngelis; Jill S Barnholtz-Sloan; Christian Grommes Journal: Neuro Oncol Date: 2018-04-09 Impact factor: 12.300
Authors: Jennie W Taylor; Eoin P Flanagan; Brian P O'Neill; Tali Siegal; Antonio Omuro; Lisa Deangelis; Joachim Baehring; Ryo Nishikawa; Fernando Pinto; Marc Chamberlain; Khe Hoang-Xuan; Alberto Gonzalez-Aguilar; Tracy Batchelor; Jean-Yves Blay; Agnieszka Korfel; Rebecca A Betensky; Maria-Beatriz S Lopes; David Schiff Journal: Neurology Date: 2013-10-09 Impact factor: 9.910
Authors: Adam Khorasanchi; Zachary Benson; Misty Hall; Nelya Ebadirad; Mohammad H Gharavi; Patrick Willard; Miranda Chimzar; John McKay; Gary Simmons; Victor Yazbeck Journal: Case Rep Hematol Date: 2022-06-21